SAVA - The Short-Sellers Have Been All Over This One... But I’ve been watching $SAVA for a while, and I gotta say, this stock is straight-up volatile. We all know the short-sellers have been hammering it — they’ve been calling out potential data manipulation, lab issues, and all that, which is exactly what you’d expect from a biotech that's still in the trial phase. Honestly, I think the shorts are the ones really driving this thing down, but here's the thing — this is biotech. It's not supposed to be easy money, right?I’m betting on the long-term thesis here. Sure, the noise around data integrity has put a lot of fear into retail, but if Simufilam proves itself in the next round of trials, we're looking at a serious player in the Alzheimer’s market. And if that happens, I can see $SAVA catching fire and exploding to the upside. But if you’re trading it, be ready for massive swings, especially when those short reports hit.For me, I'm sticking to my plan — keep a smaller position, average down if it drops, and hold for the next big catalyst. Worst-case scenario, this goes to $5 and I cut my losses, but I think there's a lot of upside here if the drug works out.Also, don’t forget about $BOLT. There’s a lot of chatter around it recently, and I think it’s looking like it could break out any time now. It’s a bit of a gamble, but I’m keeping my eye on it for a potential swing trade if the volume picks up.Anyone else feeling the same about $SAVA or $BOLT? Would love to hear thoughts on both.